|
BETABLOCKERS MAY CAUSE BRADYCARDIA & HYPOTENSION
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
BETABLOCKERS MAY CAUSE BRADYCARDIA & HYPOTENSION
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
BETABLOCKERS MAY PRODUCE BRADYCARDIA & HYPOTENSION
|
BETABLOCKERS MAY CAUSE BRADYCARDIA & HYPOTENSION
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CIMETIDINE INCREASES ITS PLASMA CONCENTRATION AND HENCE BIOAVAILABILITY
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF DISOPYRAMIDE
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
BETABLOCKERS MAY PRODUCE BRADYCARDIA & HYPOTENSION
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
PHENYTOIN ENHANCES THE DRUG METABOLISM HENCE DECREASED SERUM LEVELS HAVE BEEN OBSERVED
|
BETABLOCKERS MAY PRODUCE BRADYCARDIA & HYPOTENSION
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
BETABLOCKERS MAY PRODUCE BRADYCARDIA & HYPOTENSION
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
QUINIDINE MAY INCREASE PLASMA CONCENTRATION OF THE DRUG
|
RIFAMPICIN MAY ACCELERATES METABOLISM OF THE DRUG & MAY CAUSE DECREASED PLASMA CONCENTRATION
|
CONCURRENT USE WITH DRUGS CAUSING TORSADES PHENOMENON OR PROLONGED Q-TC INTERVAL MAY LEAD TO INCREASED CHANCES OF CARDIAC ARRHYTHMIAS
|
RIFAPENTINE INDUCES METABOLISM OF THE OTHER DRUG CAUSING DECREASED PLASMA LEVELS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
QUINIDINE MAY INCREASE PLASMA CONCENTRATION OF THE DRUG
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
DILTIAZEM INHIBIT CYP-450 ENZYME THUS REDUCING THE CLEARANCE OF THE DRUG, HENCE DOSE OF THE DRUG SHOULD BE REDUCED
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF DISOPYRAMIDE
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF DISOPYRAMIDE
|
BETABLOCKERS MAY CAUSE BRADYCARDIA & HYPOTENSION
|
FLUCONAZOLE INCREASES SERUM PLASMA CONCENTRATION OF THE DRUG
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF DISOPYRAMIDE
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
SRTRALINE INCREASES PLASMA CONCENTRATION OF THE DRUG
|
BETABLOCKERS MAY PRODUCE BRADYCARDIA & HYPOTENSION
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIARRHYTHMIC AGENTS , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIARRHYTHMIC AGENTS , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
BETABLOCKERS MAY PRODUCE BRADYCARDIA & HYPOTENSION
|
DISOPYRAMIDE SHOULD NOT BE GIVEN WITHIN 48 HRS BEFORE & 24 HRS AFTER VERAPAMIL ADMINISTRATION. THERE MAY BE EXCESSIVE WIDENING OF QRS COMPLEX AND / OR PROLONGATION OF Q-T INTERVAL
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
BETABLOCKERS MAY PRODUCE BRADYCARDIA & HYPOTENSION
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
BETABLOCKERS MAY CAUSE BRADYCARDIA & HYPOTENSION
|
FLUOXETINE MAY INCREASE PLASMA CONCENTRATION OF THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
ISONIAZID MAY INHIBIT THE METABOLISM OF THE DRUG, SO DOSE OF THE CONCURRENT DRUG SHOULD BE REDUCED
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
ITRACONAZOLE REDUCES THE DRUG METABOLISM HENCE SERUM LEVELS ARE INCREASED
|
KETOCONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
BETABLOCKERS MAY PRODUCE BRADYCARDIA & HYPOTENSION
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
FLUVOXAMINE MAY INCREASE PLASMA CONCENTRATION OF THE DRUG
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
BETABLOCKERS MAY PRODUCE BRADYCARDIA & HYPOTENSION
|
BETABLOCKERS MAY PRODUCE BRADYCARDIA & HYPOTENSION
|
PHENOBARBITONE ENHANCES DRUG METABOLISM HENCE DECREASED SERUM LEVELS OF THE DRUG HAVE BEEN OBSERVED
|
BETABLOCKERS MAY PRODUCE BRADYCARDIA & HYPOTENSION
|
INCREASED RISK OF MYOCARDIAL DEPRESSION
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
PROLONGATION OF QT INTERVAL MAY BE SERIOUS COMPLICATION
|
CAUTION IS WARRANTED & THERAPEUTIC LEVEL MONITORING IS RECOMMENDED FOR ANTIARRHYTHMICS
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
PROLONG QT INTERVAL; CO-ADMINISTRATION WITH CLASS 1A ANTIARRHYTHMIC AGENTS SHOULD BE AVOIDED
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION MAY CAUSE PROLONGATION OF Q-T INTERVAL LEADING TO INCREASED RISK OF VENTRICULAR ARRHYTHMIAS
|
INCREASES QT PROLONGATION WHICH COULD CAUSE ARRHYTHMIAS
|
INCREASES QT PROLONGATION WHICH COULD CAUSE ARRHYTHMIAS
|
INCREASES QT PROLONGATION WHICH COULD CAUSE ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIARRHYTHMIC AGENTS , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
BETABLOCKERS MAY CAUSE BRADYCARDIA & HYPOTENSION
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF DISOPYRAMIDE
|
BETABLOCKERS MAY PRODUCE BRADYCARDIA & HYPOTENSION
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
BETABLOCKERS MAY CAUSE BRADYCARDIA & HYPOTENSION
|
MICONAZOLE MAY INCREASE THE PLASMA LEVELS OF THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIARRHYTHMIC AGENTS , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIARRHYTHMIC AGENTS , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|